| Year |
Citation |
Score |
| 2021 |
Magee CP, Le BD, Siripathane YH, Wilkins DG, Hanson GR, Fleckenstein AE. Methcathinone decreases dopamine transporter function: Role of protein kinase C. Journal of Neurochemistry. PMID 34320222 DOI: 10.1111/jnc.15483 |
0.53 |
|
| 2020 |
Magee CP, German CL, Siripathane YH, Curtis PS, Anderson DJ, Wilkins DG, Hanson GR, Fleckenstein AE. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters. The Journal of Pharmacology and Experimental Therapeutics. PMID 32385092 DOI: 10.1124/Jpet.119.264895 |
0.622 |
|
| 2020 |
Magee CP, Siripathane YH, Le BD, Hanson GR, Fleckenstein AE. Methcathinone Rapidly Decreases Dopamine Transporter Function: Role of Calcium and Protein Kinase C The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04268 |
0.475 |
|
| 2016 |
Pittenger ST, Swalve N, Chou S, Smith MD, Hoonakker AJ, Pudiak CM, Fleckenstein AE, Hanson GR, Bevins RA. Sex differences in neurotensin and substance P following nicotine self-administration in rats. Synapse (New York, N.Y.). PMID 27074301 DOI: 10.1002/Syn.21907 |
0.333 |
|
| 2016 |
Baladi MG, Nielsen SM, McIntosh JM, Hanson GR, Fleckenstein AE. Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors. Behavioural Pharmacology. PMID 26871405 DOI: 10.1097/Fbp.0000000000000215 |
0.449 |
|
| 2016 |
Fricks-Gleason AN, German CL, Hoonakker AJ, Friend DM, Ganesh KK, Carver AS, Hanson GR, Fleckenstein AE, Keefe KA. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse (New York, N.Y.). PMID 26799527 DOI: 10.1002/Syn.21891 |
0.623 |
|
| 2016 |
Charntikov S, Swalve N, Pittenger S, Fink K, Schepers S, Hadlock G, Fleckenstein A, Hu G, Li M, Bevins R. Corrigendum to “Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine” [Neuropharmacology 75 (2013) 138–144] Neuropharmacology. 101: 590. DOI: 10.1016/J.Neuropharm.2015.03.025 |
0.751 |
|
| 2015 |
German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. Pharmacological Reviews. 67: 1005-24. PMID 26408528 DOI: 10.1124/Pr.114.010397 |
0.579 |
|
| 2015 |
Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE. Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits. The Journal of Pharmacology and Experimental Therapeutics. PMID 26391161 DOI: 10.1124/Jpet.114.221945 |
0.346 |
|
| 2015 |
Vieira-Brock PL, McFadden LM, Nielsen SM, Smith MD, Hanson GR, Fleckenstein AE. Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 26164716 DOI: 10.1093/Ijnp/Pyv073 |
0.304 |
|
| 2015 |
McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure. Neuropharmacology. 93: 146-54. PMID 25645392 DOI: 10.1016/J.Neuropharm.2015.01.013 |
0.519 |
|
| 2015 |
Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug and Alcohol Dependence. 146: 30-8. PMID 25479916 DOI: 10.1016/J.Drugalcdep.2014.10.027 |
0.455 |
|
| 2015 |
Hanson GR, Fleckenstein AE, Curtin K. Dependence on amphetamines increases Parkinson's disease: Effect of gender Drug and Alcohol Dependence. 146: e134-e135. DOI: 10.1016/J.Drugalcdep.2014.09.284 |
0.302 |
|
| 2014 |
Baladi MG, Nielsen SM, Umpierre A, Hanson GR, Fleckenstein AE. Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats. Behavioural Pharmacology. 25: 758-65. PMID 25325290 DOI: 10.1097/Fbp.0000000000000094 |
0.404 |
|
| 2014 |
German CL, Alburges ME, Hoonakker AJ, Fleckenstein AE, Hanson GR. Mephedrone alters basal ganglia and limbic dynorphin systems. Synapse (New York, N.Y.). PMID 25155699 DOI: 10.1002/Syn.21778 |
0.493 |
|
| 2014 |
Baladi MG, Newman AH, Nielsen SM, Hanson GR, Fleckenstein AE. Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. European Journal of Pharmacology. 732: 105-10. PMID 24685638 DOI: 10.1016/J.Ejphar.2014.03.023 |
0.592 |
|
| 2014 |
German CL, Hoonakker AH, Fleckenstein AE, Hanson GR. Mephedrone alters basal ganglia and limbic neurotensin systems. Journal of Neurochemistry. 130: 402-7. PMID 24678634 DOI: 10.1111/Jnc.12727 |
0.49 |
|
| 2014 |
McFadden LM, Vieira-Brock PL, Hanson GR, Fleckenstein AE. Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 1315-20. PMID 24650575 DOI: 10.1017/S1461145714000327 |
0.422 |
|
| 2014 |
German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sciences. 97: 2-8. PMID 23911668 DOI: 10.1016/J.Lfs.2013.07.023 |
0.328 |
|
| 2013 |
Charntikov S, Swalve N, Pittenger S, Fink K, Schepers S, Hadlock GC, Fleckenstein AE, Hu G, Li M, Bevins RA. Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine. Neuropharmacology. 75: 138-44. PMID 23916479 DOI: 10.1016/J.Neuropharm.2013.07.019 |
0.794 |
|
| 2013 |
McFadden LM, Hanson GR, Fleckenstein AE. The effects of methamphetamine self-administration on cortical monoaminergic deficits induced by subsequent high-dose methamphetamine administrations. Synapse (New York, N.Y.). 67: 875-81. PMID 23893609 DOI: 10.1002/Syn.21696 |
0.412 |
|
| 2013 |
Fleckenstein AE, Hanson GR. Psychostimulant-Induced Alterations of Monoaminergic Transporters: Implications for Neurotoxicity and Neuroprotection Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 47. DOI: 10.1016/B978-0-12-800044-1.00041-6 |
0.374 |
|
| 2012 |
German CL, Hanson GR, Fleckenstein AE. Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. Journal of Neurochemistry. 123: 288-97. PMID 22804716 DOI: 10.1111/J.1471-4159.2012.07875.X |
0.647 |
|
| 2012 |
McFadden LM, Hunt MM, Vieira-Brock PL, Muehle J, Nielsen SM, Allen SC, Hanson GR, Fleckenstein AE. Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug and Alcohol Dependence. 126: 87-94. PMID 22647900 DOI: 10.1016/J.Drugalcdep.2012.04.020 |
0.456 |
|
| 2012 |
McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse (New York, N.Y.). 66: 240-5. PMID 22120988 DOI: 10.1002/Syn.21506 |
0.55 |
|
| 2012 |
McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. The Journal of Pharmacology and Experimental Therapeutics. 340: 295-303. PMID 22034657 DOI: 10.1124/Jpet.111.188433 |
0.832 |
|
| 2011 |
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. The Journal of Pharmacology and Experimental Therapeutics. 339: 530-6. PMID 21810934 DOI: 10.1124/Jpet.111.184119 |
0.838 |
|
| 2011 |
Ellis JD, German CL, Birdsall E, Hanson JE, Crosby MA, Rowley SD, Sawada NA, West JN, Hanson GR, Fleckenstein AE. Ephedrine decreases vesicular monoamine transporter-2 function. Synapse (New York, N.Y.). 65: 449-51. PMID 21370280 DOI: 10.1002/Syn.20896 |
0.496 |
|
| 2011 |
Alburges ME, Hoonakker AJ, Horner KA, Fleckenstein AE, Hanson GR. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. Journal of Neurochemistry. 117: 470-8. PMID 21323925 DOI: 10.1111/J.1471-4159.2011.07215.X |
0.556 |
|
| 2011 |
Hadlock GC, Nelson CC, Baucum AJ, Hanson GR, Fleckenstein AE. Ex vivo identification of protein-protein interactions involving the dopamine transporter. Journal of Neuroscience Methods. 196: 303-7. PMID 21291912 DOI: 10.1016/J.Jneumeth.2011.01.023 |
0.782 |
|
| 2011 |
McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse (New York, N.Y.). 65: 771-7. PMID 21190217 DOI: 10.1002/Syn.20902 |
0.466 |
|
| 2011 |
Frankel PS, Hoonakker AJ, Alburges ME, McDougall JW, McFadden LM, Fleckenstein AE, Hanson GR. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. The Journal of Pharmacology and Experimental Therapeutics. 336: 809-15. PMID 21131268 DOI: 10.1124/Jpet.110.176610 |
0.488 |
|
| 2010 |
Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. Journal of Neurochemistry. 115: 325-32. PMID 20649837 DOI: 10.1111/J.1471-4159.2010.06922.X |
0.824 |
|
| 2010 |
Hadlock GC, Chu PW, Walters ET, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 335: 207-12. PMID 20622144 DOI: 10.1124/Jpet.110.166660 |
0.839 |
|
| 2009 |
Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue. Journal of Neuroscience Methods. 180: 317-20. PMID 19464519 DOI: 10.1016/J.Jneumeth.2009.03.015 |
0.595 |
|
| 2009 |
Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. European Journal of Pharmacology. 607: 68-73. PMID 19326567 DOI: 10.1016/J.Ejphar.2009.01.037 |
0.606 |
|
| 2009 |
Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. The Journal of Pharmacology and Experimental Therapeutics. 329: 169-74. PMID 19141713 DOI: 10.1124/Jpet.108.145631 |
0.832 |
|
| 2009 |
Farnsworth SJ, Volz TJ, Hanson GR, Fleckenstein AE. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 328: 807-12. PMID 19038779 DOI: 10.1124/Jpet.108.146159 |
0.579 |
|
| 2009 |
Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity. Synapse (New York, N.Y.). 63: 147-51. PMID 19021208 DOI: 10.1002/Syn.20580 |
0.614 |
|
| 2009 |
Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles. Journal of Neuroscience Methods. 177: 177-82. PMID 18992277 DOI: 10.1016/J.Jneumeth.2008.10.004 |
0.543 |
|
| 2009 |
Fleckenstein AE, Volz TJ, Hanson GR. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology. 56: 133-8. PMID 18662707 DOI: 10.1016/J.Neuropharm.2008.07.002 |
0.578 |
|
| 2008 |
Volz TJ, Farnsworth SJ, Hanson GR, Fleckenstein AE. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity. Annals of the New York Academy of Sciences. 1139: 285-90. PMID 18991873 DOI: 10.1196/Annals.1432.012 |
0.56 |
|
| 2008 |
Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, Fleckenstein AE. Differential regional effects of methamphetamine on dopamine transport. European Journal of Pharmacology. 590: 105-10. PMID 18599036 DOI: 10.1016/J.Ejphar.2008.05.028 |
0.764 |
|
| 2008 |
Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 327: 161-7. PMID 18591219 DOI: 10.1124/Jpet.108.139386 |
0.551 |
|
| 2008 |
Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects Drug Addiction: From Basic Research to Therapy. 169-177. DOI: 10.1007/978-0-387-76678-2_11 |
0.761 |
|
| 2007 |
Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. The Journal of Pharmacology and Experimental Therapeutics. 323: 738-45. PMID 17693585 DOI: 10.1124/Jpet.107.126888 |
0.809 |
|
| 2007 |
Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. European Journal of Pharmacology. 571: 25-8. PMID 17618619 DOI: 10.1016/J.Ejphar.2007.05.044 |
0.8 |
|
| 2007 |
Volz TJ, Fleckenstein AE, Hanson GR. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction (Abingdon, England). 102: 44-8. PMID 17493052 DOI: 10.1111/J.1360-0443.2007.01771.X |
0.618 |
|
| 2007 |
Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. Journal of Neurochemistry. 101: 883-8. PMID 17250674 DOI: 10.1111/J.1471-4159.2006.04419.X |
0.631 |
|
| 2007 |
Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG. Persistence of tolerance to methamphetamine-induced monoamine deficits. European Journal of Pharmacology. 559: 46-54. PMID 17239369 DOI: 10.1016/J.Ejphar.2006.11.045 |
0.701 |
|
| 2007 |
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology. 47: 681-98. PMID 17209801 DOI: 10.1146/Annurev.Pharmtox.47.120505.105140 |
0.821 |
|
| 2006 |
Rau KS, Truong JG, Wilkins DG, Fleckenstein AE, Hanson GR. Age-dependent effects of methamphetamine on VMAT-2. Annals of the New York Academy of Sciences. 1074: 154-9. PMID 17105913 DOI: 10.1196/Annals.1369.015 |
0.521 |
|
| 2006 |
Volz TJ, Hanson GR, Fleckenstein AE. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse (New York, N.Y.). 60: 474-7. PMID 16897727 DOI: 10.1002/Syn.20321 |
0.541 |
|
| 2006 |
Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. The Aaps Journal. 8: E413-8. PMID 16808044 DOI: 10.1007/Bf02854914 |
0.774 |
|
| 2006 |
Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ, Adair BP, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake. The Journal of Pharmacology and Experimental Therapeutics. 318: 676-82. PMID 16687477 DOI: 10.1124/Jpet.105.099200 |
0.823 |
|
| 2006 |
Volz TJ, Hanson GR, Fleckenstein AE. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. Journal of Neuroscience Methods. 155: 109-15. PMID 16480775 DOI: 10.1016/J.Jneumeth.2006.01.002 |
0.546 |
|
| 2005 |
Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. The Aaps Journal. 7: E847-51. PMID 16594636 DOI: 10.1208/Aapsj070481 |
0.822 |
|
| 2005 |
Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology. 49: 820-30. PMID 16005476 DOI: 10.1016/J.Neuropharm.2005.05.004 |
0.803 |
|
| 2005 |
Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics. 314: 1087-92. PMID 15901804 DOI: 10.1124/Jpet.105.085951 |
0.775 |
|
| 2004 |
Hanson GR, Sandoval V, Riddle E, Fleckenstein AE. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Annals of the New York Academy of Sciences. 1025: 146-50. PMID 15542712 DOI: 10.1196/Annals.1316.019 |
0.855 |
|
| 2004 |
Truong JG, Newman AH, Hanson GR, Fleckenstein AE. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. European Journal of Pharmacology. 504: 27-32. PMID 15507217 DOI: 10.1016/J.Ejphar.2004.09.049 |
0.583 |
|
| 2004 |
Hanson GR, Rau KS, Fleckenstein AE. The methamphetamine experience: a NIDA partnership. Neuropharmacology. 47: 92-100. PMID 15464128 DOI: 10.1016/J.Neuropharm.2004.06.004 |
0.559 |
|
| 2004 |
Truong JG, Hanson GR, Fleckenstein AE. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. European Journal of Pharmacology. 492: 143-7. PMID 15178358 DOI: 10.1016/J.Ejphar.2004.03.060 |
0.627 |
|
| 2004 |
Baucum AJ, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 3436-43. PMID 15056723 DOI: 10.1523/Jneurosci.0387-04.2004 |
0.856 |
|
| 2004 |
Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 309: 578-86. PMID 14747615 DOI: 10.1124/Jpet.103.062695 |
0.809 |
|
| 2003 |
Johnson-Davis KL, Fleckenstein AE, Wilkins DG. The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. European Journal of Pharmacology. 482: 151-4. PMID 14660016 DOI: 10.1016/J.Ejphar.2003.09.063 |
0.746 |
|
| 2003 |
Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. European Journal of Pharmacology. 479: 283-9. PMID 14612158 DOI: 10.1016/J.Ejphar.2003.08.077 |
0.536 |
|
| 2003 |
Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. European Journal of Pharmacology. 474: 223-6. PMID 12921866 DOI: 10.1016/S0014-2999(03)02080-6 |
0.602 |
|
| 2003 |
Ugarte YV, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors. European Journal of Pharmacology. 472: 165-71. PMID 12871750 DOI: 10.1016/S0014-2999(03)01911-3 |
0.847 |
|
| 2003 |
Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. The Journal of Pharmacology and Experimental Therapeutics. 304: 1181-7. PMID 12604695 DOI: 10.1124/Jpet.102.045005 |
0.861 |
|
| 2003 |
Riddle EL, Rau KS, Topham MK, Hanson GR, Fleckenstein AE. Ceramide-induced alterations in dopamine transporter function. European Journal of Pharmacology. 458: 31-6. PMID 12498904 DOI: 10.1016/S0014-2999(02)02727-9 |
0.823 |
|
| 2002 |
Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, Fleckenstein AE. Inhibitory effect of reserpine on dopamine transporter function. European Journal of Pharmacology. 456: 39-43. PMID 12450567 DOI: 10.1016/S0014-2999(02)02647-X |
0.799 |
|
| 2002 |
Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8705-10. PMID 12351745 DOI: 10.1523/Jneurosci.22-19-08705.2002 |
0.862 |
|
| 2002 |
Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. European Journal of Pharmacology. 449: 71-4. PMID 12163108 DOI: 10.1016/S0014-2999(02)01985-4 |
0.816 |
|
| 2002 |
Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. The Journal of Pharmacology and Experimental Therapeutics. 302: 497-501. PMID 12130707 DOI: 10.1124/Jpet.302.2.497 |
0.86 |
|
| 2002 |
Crosby MJ, Hanson JE, Fleckenstein AE, Hanson GR. Phencyclidine increases vesicular dopamine uptake. European Journal of Pharmacology. 438: 75-8. PMID 11906713 DOI: 10.1016/S0014-2999(02)01298-0 |
0.606 |
|
| 2002 |
Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics. 300: 1093-100. PMID 11861820 DOI: 10.1124/Jpet.300.3.1093 |
0.873 |
|
| 2002 |
Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. Tolerance to the neurotoxic effects of methamphetamine in young rats. European Journal of Pharmacology. 435: 181-5. PMID 11821024 DOI: 10.1016/S0014-2999(01)01592-8 |
0.788 |
|
| 2001 |
Brown JM, Hanson GR, Fleckenstein AE. Cocaine-induced increases in vesicular dopamine uptake: Role of dopamine receptors Journal of Pharmacology and Experimental Therapeutics. 298: 1150-1153. PMID 11504813 |
0.513 |
|
| 2001 |
Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants Journal of Pharmacology and Experimental Therapeutics. 296: 762-767. PMID 11181904 |
0.536 |
|
| 2001 |
Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 1413-9. PMID 11160413 DOI: 10.1523/Jneurosci.21-04-01413.2001 |
0.851 |
|
| 2000 |
Sandoval V, Hanson GR, Fleckenstein AE. Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. European Journal of Pharmacology. 409: 265-71. PMID 11108820 DOI: 10.1016/S0014-2999(00)00871-2 |
0.805 |
|
| 2000 |
Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. The Journal of Pharmacology and Experimental Therapeutics. 295: 1077-85. PMID 11082443 |
0.565 |
|
| 2000 |
Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine Journal of Neurochemistry. 75: 2095-2102. PMID 11032899 DOI: 10.1046/J.1471-4159.2000.0752095.X |
0.49 |
|
| 2000 |
Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity European Journal of Pharmacology. 406: 1-13. PMID 11011026 DOI: 10.1016/S0014-2999(00)00639-7 |
0.555 |
|
| 2000 |
Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR. The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. Journal of Neurochemistry. 75: 1608-17. PMID 10987842 DOI: 10.1046/J.1471-4159.2000.0751608.X |
0.616 |
|
| 2000 |
Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake Journal of Neurochemistry. 74: 2221-2223. PMID 10800970 DOI: 10.1046/J.1471-4159.2000.0742221.X |
0.636 |
|
| 2000 |
Haughey HM, Brown JM, Wilkins DG, Hanson GR, Fleckenstein AE. Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Research. 863: 59-65. PMID 10773193 DOI: 10.1016/S0006-8993(00)02094-1 |
0.567 |
|
| 2000 |
Hentschel K, Fleckenstein AE, Toney TW, Lawson DM, Moore KE, Lookingland KJ. Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies. Brain Research. 852: 28-36. PMID 10661492 DOI: 10.1016/S0006-8993(99)02182-4 |
0.454 |
|
| 1999 |
Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW, Hanson GR. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. European Journal of Pharmacology. 382: 45-9. PMID 10556503 DOI: 10.1016/S0014-2999(99)00588-9 |
0.837 |
|
| 1999 |
Haughey HM, Brown JM, Fleckenstein AE, Hanson GR. Oxygen radicals differentially affect Na+/Cl(-)-dependent transporters. European Journal of Pharmacology. 379: 107-10. PMID 10499378 DOI: 10.1016/S0014-2999(99)00487-2 |
0.504 |
|
| 1999 |
Haughey HM, Fleckenstein AE, Hanson GR. Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. Journal of Neurochemistry. 72: 661-8. PMID 9930738 DOI: 10.1046/J.1471-4159.1999.0720661.X |
0.395 |
|
| 1998 |
Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE. Methamphetamine-Induced Rapid and Reversible Reduction in the Activities of Tryptophan Hydroxylase and Dopamine Transporters: Oxidative Consequences?(a). Annals of the New York Academy of Sciences. 844: 103-107. PMID 29090817 DOI: 10.1111/J.1749-6632.1998.Tb08225.X |
0.535 |
|
| 1998 |
Kokoshka JM, Vaughan RA, Hanson GR, Fleckenstein AE. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters European Journal of Pharmacology. 361: 269-275. PMID 9865517 DOI: 10.1016/S0014-2999(98)00741-9 |
0.6 |
|
| 1998 |
Metzger RR, Hanson GR, Gibb JW, Fleckenstein AE. 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. European Journal of Pharmacology. 349: 205-10. PMID 9671099 DOI: 10.1016/S0014-2999(98)00196-4 |
0.625 |
|
| 1998 |
Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE. Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences? Annals of the New York Academy of Sciences. 844: 103-7. PMID 9668668 DOI: 10.1111/j.1749-6632.1998.tb08225.x |
0.444 |
|
| 1998 |
Kokoshka JM, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Research. 799: 78-83. PMID 9666084 DOI: 10.1016/S0006-8993(98)00472-7 |
0.539 |
|
| 1997 |
Gygi MP, Fleckenstein AE, Gibb JW, Hanson GR. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone Journal of Pharmacology and Experimental Therapeutics. 283: 1350-1355. PMID 9400010 |
0.539 |
|
| 1997 |
Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, Hanson GR. Oxygen radicals diminish dopamine transporter function in rat striatum European Journal of Pharmacology. 334: 111-114. PMID 9346337 DOI: 10.1016/S0014-2999(97)01175-8 |
0.546 |
|
| 1997 |
Fleckenstein AE. Effect of methamphetamine on tryptophan hydroxylase activity: Role of hyperthermia European Journal of Pharmacology. 332: 263-265. PMID 9300258 DOI: 10.1016/S0014-2999(97)01095-9 |
0.38 |
|
| 1997 |
Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. Rapid and reversible effects of methamphetamine on dopamine transporters Journal of Pharmacology and Experimental Therapeutics. 282: 834-838. PMID 9262348 |
0.535 |
|
| 1997 |
Fleckenstein AE, Beyeler ML, Jackson JC, Wilkins DG, Gibb JW, Hanson GR. Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters. European Journal of Pharmacology. 324: 179-86. PMID 9145769 DOI: 10.1016/S0014-2999(97)00081-2 |
0.565 |
|
| 1997 |
Fleckenstein AE, Metzger RR, Gibb JW, Hanson GR. A rapid and reversible change in dopamine transporters induced by methamphetamine European Journal of Pharmacology. 323: R9-R10. PMID 9128855 DOI: 10.1016/S0014-2999(97)00148-9 |
0.625 |
|
| 1996 |
Fleckenstein AE, Kopajtic TA, Boja JW, Carroll FI, Kuhar MJ. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. European Journal of Pharmacology. 311: 109-14. PMID 8891589 DOI: 10.1016/0014-2999(96)00423-2 |
0.449 |
|
| 1996 |
Fleckenstein AE, Pögün S, Carroll FI, Kuhar MJ. Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 beta-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride]. The Journal of Pharmacology and Experimental Therapeutics. 279: 200-6. PMID 8858994 |
0.406 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Differential effects of histamine on the activity of hypothalamic dopaminergic neurons in the rat. The Journal of Pharmacology and Experimental Therapeutics. 268: 270-6. PMID 8301567 |
0.339 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Histaminergic neurons mediate restraint stress-induced increases in the activity of noradrenergic neurons projecting to the hypothalamus. Brain Research. 653: 273-7. PMID 7982061 DOI: 10.1016/0006-8993(94)90400-6 |
0.32 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Differential role of histamine in mediating stress-induced changes in central dopaminergic neuronal activity in the rat. Brain Research. 653: 267-72. PMID 7982060 DOI: 10.1016/0006-8993(94)90399-9 |
0.365 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Activation of noradrenergic neurons projecting to the diencephalon following central administration of histamine is mediated by H1 receptors. Brain Research. 638: 243-7. PMID 7911061 DOI: 10.1016/0006-8993(94)90656-4 |
0.356 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Histaminergic neurons mediate restraint stress-induced activation of central 5-hydroxytryptaminergic neurons in the rat. European Journal of Pharmacology. 264: 163-7. PMID 7531644 DOI: 10.1016/0014-2999(94)00461-7 |
0.349 |
|
| 1994 |
Fleckenstein AE, Lookingland KJ, Moore KE. Effects of histamine on 5-hydroxytryptaminergic neuronal activity in the rat hypothalamus. European Journal of Pharmacology. 254: 35-42. PMID 7515820 DOI: 10.1016/0014-2999(94)90367-0 |
0.378 |
|
| 1993 |
Fleckenstein AE, Lookingland KJ, Moore KE. Activation of mesolimbic dopaminergic neurons following central administration of histamine is mediated by H1 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 347: 50-4. PMID 8446183 DOI: 10.1007/Bf00168771 |
0.478 |
|
| 1992 |
Fleckenstein AE, Lookingland KJ, Moore KE. Evidence that histamine-stimulated prolactin secretion is not mediated by an inhibition of tuberoinfundibular dopaminergic neurons. Life Sciences. 51: 741-6. PMID 1513202 DOI: 10.1016/0024-3205(92)90483-6 |
0.482 |
|
| 1992 |
Toney TW, Pawsat DE, Fleckenstein AE, Lookingland KJ, Moore KE. Evidence that prolactin mediates the stimulatory effects of estrogen on tuberoinfundibular dopamine neurons in female rats. Neuroendocrinology. 55: 282-9. PMID 1323801 DOI: 10.1159/000126127 |
0.412 |
|
| Show low-probability matches. |